Why the study?
Should cyclooxygenase-2 selective inhibitors be used in emergency departments in Australasia?
Should cyclooxygenase-2 selective inhibitors be used in emergency departments in Australasia?
This review evaluates the pharmacology, effectiveness, and safety of COX-2 inhibitors to determine their role in emergency department prescribing in Australasia.
Answers are grounded in this paper and cite their sources.
Role of COX-2 inhibitors in Australasian EDs remains uncertain; prospective trials needed before routine use.
Cyclooxygenase-2 selective inhibitors (COXIB or CSI) have been released with a fanfare as efficacious and safer alternatives to traditional non-steroidal anti-inflammatory drugs. They purport to offer equivalent degrees of analgesia and an improved safety profile. COXIB currently available in Australasia are celecoxib (Celebrex), rofecoxib (Vioxx) and etoricoxib (Arcoxia). This review discusses the pharmacology of these agents and reviews recent literature regarding their effectiveness and safety. It endeavours to answer the question 'Should we be using COXIB in emergency departments in Australasia'?
No takes yet. Share an insight, caveat, or question.
Tanya Wilton (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: